jeudi 2 janvier 2020

Onco Actu du 2 janvier 2020


1. BIOLOGIE



Researchers identify immune-suppressing target in glioblastoma [MD Anderson Cancer Center]











2.6 ETIOLOGIE - ENVIRONNEMENT



U.S. government says verdict in Bayer's Roundup case should be reversed [Reuters]











USRTK, Carey Gillam Collaborated With Monsanto Plaintiff Attorney Charged With Extortion [ACSH]











3.1 PRÉVENTION - TABAC



Why Tobacco Industry Giants Backed Raising The Minimum Age Of Purchase [NPR]











Drive to add 'stop smoking' to new year's resolutions scrapped by Public Health England [The Telegrah]











Stop smoking campaign in England axed after health budget cuts [The Guardian]











3.1.1 PRÉVENTION - TABAC - E-CIGS



E-cigarettes are still safer than smoking, scientists find [The Guardian]











F.D.A. Plans to Ban Most E-Cigarette Flavors but Menthol [NY Times]











Trump says vaping decision coming shortly, hopes flavors can return to market fast [Reuters]











CDC Confirms A THC Additive, Vitamin E Acetate, Is The Culprit In Most Vaping Deaths [NPR]











New evidence strengthens link between vitamin E acetate and vaping illness [STAT]










Vaping Patients May Be Prone to Relapse, C.D.C. Warns [NY Times]











3.3 PRÉVENTION - VACCINS



Women with single dose of HPV vaccine gain similar protection as multiple doses [UT Health]










3.6 PRÉVENTION - ACTIVITÉ PHYSIQUE



Report Links Recommended Physical Activity Levels to Lower Risk of Seven Cancers [ACS]










4.1 DÉP., DIAG. & PRONO. - PROSTATE



Prostate Cancer Modeling Study Supports Precision Screening Approach [Genome Web]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



A Genetic Test Led Seven Women in One Family to Have Major Surgery. Then the Odds Changed. [Wall Street Journal]










4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS



Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer [Myriad]











Myriad Data Supports Polygenic Score Value Even in Canonical Mutation Carriers [Genome Web]











4.9 DÉP., DIAG. & PRONO. - SEIN



Google AI tool can pinpoint breast cancer better than clinicians, new study suggests [STAT]











A.I. Is Learning to Read Mammograms [NY Times]










AI system outperforms experts in spotting breast cancer [The Guardian]











Study finds Google system could improve breast cancer detection [Reuters]











5.12.10 IMMUNOTHÉRAPIES - FUSIONS ET ACQUISITIONS



Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc. [Astellas]











On a spree, Astellas bags a next-gen, Parker-backed CAR-T platform with $665M buyout deal [EndPoints]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Armed antibodies for cancer immunotherapy: DKFZ and DKTK scientists granted patent for innovative antibody design [DKFZ]











5.12.13 IMMUNOTHÉRAPIES - BIOMARQUEURS



Study links common immune cell to failure of checkpoint inhibitors in lung cancer [Fred Hutch]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



To make advanced therapies, we need to industrialize personalization [STAT]










5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH



Banking on Shanghai's biotech boom, this Eli Lilly-backed biotech grabs $100M to push next-gen I/O therapies [EndPoints]











5.2 PHARMA



Bristol-Myers Squibb Receives European Commission Approval for Revlimid® (lenalidomide) in Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma [BMS]











Spectrum shares crater as first round of pivotal data for their TKI falls short of primary endpoint [EndPoints]











5.2.2 PHARMA - FUSIONS & ACQUISITIONS



Johnson & Johnson Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer [Johnson & Johnson]











5.3.4.1 TRAITEMENTS - AMM (FDA, EMA,...) - ENHERTU



Daiichi, AstraZeneca breast cancer drug joins bumper crop of early FDA approvals [Biopharma Dive]











AstraZeneca, Daiichi notch blockbuster FDA nod for breast cancer med Enhertu [Fierce Pharma]











Enhertu (trastuzumab deruxtecan) approved in the US for HER2-positive unresectable or metastatic breast cancer following two or more prior anti-HER2 based regimens [AstraZeneca]











FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies [FDA]











Why wait? The FDA stamps an ultra-fast OK on a HER2+ drug expected to create AstraZeneca's next blockbuster franchise [EndPoints]










AstraZeneca, Daiichi's breast cancer drug gets accelerated approval from FDA [Reuters]











5.3.4.2 TRAITEMENTS - AMM (FDA, EMA,...) - LYNPARZA



Despite questionable PARP data, FDA stamps quick OK on Lynparza as a frontline therapy for pancreatic cancer [EndPoints]










AstraZeneca, Merck's Lynparza lands FDA nod in tough-to-treat pancreatic cancer [Fierce Pharma]











Lynparza approved in the US as a 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer [AstraZeneca]











AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer [Reuters]











5.4 TRAITEMENTS - ECONOMIE



Exclusive: Drugmakers from Pfizer to GSK to hike U.S. prices on over 200 drugs [Reuters]











6. LUTTE CONTRE LES CANCERS



Precision medicine has a blind spot: children with cancer [STAT]










6.3 ASSOCIATIONS/FONDATIONS



More cancer patients turning away from NHS for advice – Macmillan [The Guardian]